Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Trial Profile

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs NEOD 001 (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Adverse reactions
  • Acronyms OLE
  • Sponsors Prothena
  • Most Recent Events

    • 10 Aug 2016 Status changed from not yet recruiting to active, no longer recruiting.
    • 27 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top